Edition:
United States

Profile: Agenus Inc (AGEN.O)

AGEN.O on Consolidated Issue listed on NASDAQ Capital Market

4.26USD
23 Oct 2017
Change (% chg)

$-0.07 (-1.62%)
Prev Close
$4.33
Open
$4.86
Day's High
$4.90
Day's Low
$4.20
Volume
12,224,921
Avg. Vol
1,239,867
52-wk High
$5.98
52-wk Low
$3.20

Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.

Company Address

Agenus Inc

3 Forbes Rd
LEXINGTON   MA   02421-7305
P: +1781.6744410
F: +1781.6744200

Company Web Links